Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Buy Tesamorelin/Ipamorelin/CJC-1295 Blend - Vial

Buy Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Research Peptide Online This multi-component peptide blend combines tesamorelin, CJC-1295 (growth hormone-releasing factor analog), and ipamorelin (growth hormone secretagogue) in a 12mg formulation for advanced preclinical investigation of somatotropic axis function. The synergistic combination enables comprehensive research into multi-pathway growth hormone secretion modulation mechanisms. Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Peptide Composition & Classification The blend comprises three distinct growth hormone-stimulating compounds: tesamorelin (GHRH agonist), CJC-1295 (GRF-1(1-29)NH2 analog with enhanced stability), and ipamorelin (pentapeptide GHS-R agonist). Combined formulation permits investigation of complementary mechanisms affecting growth hormone secretion and axis regulation in preclinical research models. Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Mechanism of Action in Research Systems Tesamorelin activates GHRH

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Buy Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Research Peptide Online

This multi-component peptide blend combines tesamorelin, CJC-1295 (growth hormone-releasing factor analog), and ipamorelin (growth hormone secretagogue) in a 12mg formulation for advanced preclinical investigation of somatotropic axis function. The synergistic combination enables comprehensive research into multi-pathway growth hormone secretion modulation mechanisms.

Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Peptide Composition & Classification

The blend comprises three distinct growth hormone-stimulating compounds: tesamorelin (GHRH agonist), CJC-1295 (GRF-1(1-29)NH2 analog with enhanced stability), and ipamorelin (pentapeptide GHS-R agonist). Combined formulation permits investigation of complementary mechanisms affecting growth hormone secretion and axis regulation in preclinical research models.

Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Mechanism of Action in Research Systems

Tesamorelin activates GHRH receptors on somatotrophs. CJC-1295 similarly engages GHRH-R through GRF-analog mechanisms with extended half-life. Ipamorelin acts via distinct ghrelin receptor (GHS-R1a) pathways. Preclinical studies document synergistic growth hormone secretion when multiple agonists combine, enabling investigation of axis-level integration in controlled systems.

Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Published Research Summary

Literature documents individual peptide pharmacology extensively. Peer-reviewed research in Journal of Endocrinological Investigation and Neuroendocrinology examines GHRH and GHS-R agonism separately. Combination studies provide insights into multi-pathway regulation of somatotropic function in animal models and cell culture systems.

Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Product Specifications & Handling

– Form: Lyophilized powder blend (acetate salts) – Quantity: 12mg total – Composition: Tesamorelin, CJC-1295, ipamorelin (proprietary ratio) – Purity: Research-grade (98%+) – Storage: -20°C freezer; protect from light and moisture – Reconstitution: Sterile saline; room temperature equilibration – Stability: 2-3 weeks refrigerated post-reconstitution

Tesamorelin, CJC-1295, Ipamorelin 12mg Blend Research Use Only Disclaimer

This blend is intended exclusively for preclinical research and in vitro investigation. Not approved for human consumption, veterinary use, or clinical application. All use must comply with institutional research protocols.

Connected topics

Follow this recovery question